Elacridar (GF120918: GW0918) is a P-glycoprotein inhibitor and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules. A prototypical
Elacridar (GF120918: GW0918) is a P-glycoprotein inhibitor and has been used both in vitro and in vivo as a tool inhibitor of P-glycoprotein (Pgp) to investigate the role of transporters in the disposition of various test molecules. A prototypical
InformationELR-510444 ELR-510444 is a novel microtubule disruptor with potential antivascular effects and in vivo antitumor efficacy, causing a loss of cellular microtubules and the formation of aberrant mitotic spindles and leading to mitotic
InformationELR-510444 ELR-510444 is a novel microtubule disruptor with potential antivascular effects and in vivo antitumor efficacy, causing a loss of cellular microtubules and the formation of aberrant mitotic spindles and leading to mitotic
InformationElimusertib (BAY-1895344) is a very potent and highly selectiveATR (ataxia telangiectasia and Rad3-related)inhibitor with IC50 of 7 nM. Elimusertib potently inhibits proliferation of a broad spectrum of human tumor cell lines with median
InformationElimusertib (BAY-1895344) is a very potent and highly selectiveATR (ataxia telangiectasia and Rad3-related)inhibitor with IC50 of 7 nM. Elimusertib potently inhibits proliferation of a broad spectrum of human tumor cell lines with median